Veradermics posts corporate deck highlighting VDPHL01 oral minoxidil program for pattern hair loss

VeraDermics

VeraDermics

MANE

0.00
  • Veradermics outlined late-stage plans for VDPHL01, an extended-release oral minoxidil tablet for pattern hair loss.
  • Study 302 topline data showed statistically significant non-vellus target area hair count gains at month 6: 30.3 hairs (8.5 mg QD) or 33.0 (8.5 mg BID) vs 7.3 placebo.
  • Study 304, a phase 3 trial in 552 men, is fully enrolled, with a 6-month topline readout expected in H2 2026.
  • Study 306, a phase 2/3 program in women, is actively enrolling, targeting an oral option in a market the deck sizes at about 80 million US patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.